WO2007087135A2 - PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS - Google Patents
PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS Download PDFInfo
- Publication number
- WO2007087135A2 WO2007087135A2 PCT/US2007/000231 US2007000231W WO2007087135A2 WO 2007087135 A2 WO2007087135 A2 WO 2007087135A2 US 2007000231 W US2007000231 W US 2007000231W WO 2007087135 A2 WO2007087135 A2 WO 2007087135A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperazin
- ethanone
- phenyl
- benzyloxy
- ylmethoxy
- Prior art date
Links
- 0 CC(C)(C)OC(N(CC1)C(C*=C)CN1c(ccc(Cl)c1)c1Cl)=O Chemical compound CC(C)(C)OC(N(CC1)C(C*=C)CN1c(ccc(Cl)c1)c1Cl)=O 0.000 description 2
- GNUHDAKKEDREMW-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c(c(F)c1)ccc1Cl)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c(c(F)c1)ccc1Cl)=O GNUHDAKKEDREMW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a new class of compounds, to pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
- the invention further relates to the process for the preparation of said compounds and to new intermediates prepared therein.
- Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system (CNS). Glutamate produces its effects on central neurons by binding to and thereby activating cell surface receptors. These receptors have been divided into two major classes, the ionotropic and metabotropic glutamate receptors, based on the structural features of the receptor proteins, the means by which the receptors transduce signals into the cell, and pharmacological profiles.
- the metabotropic glutamate receptors are G protein-coupled receptors that activate a variety of intracellular second messenger systems following the binding of glutamate. Activation of mGluRs in intact mammalian neurons elicits one or more of the following responses: activation of phospholipase C; increases in phosphoinositide (PI) hydrolysis; intracellular calcium release; activation of phospholipase D; activation or inhibition of adenyl cyclase; increases or decreases in the formation of cyclic adenosine monophosphate (cAMP); activation of guanylyl cyclase; increases in the formation of cyclic guanosine monophosphate (cGMP); activation of phospholipase A 2 ; increases in arachidonic acid release; and increases or decreases in the activity of voltage- and ligand-gated ion channels.
- PI phosphoinositide
- cAMP cyclic adenosine monophosphate
- mGluRl through mGluR8.
- Nakanishi Neuron /3:1031 (1994)
- Pin et al Neuropharmacology 34:1 (1995), Knopfel et al, J. Med. Chem. JS: 1417 (1995).
- Further receptor diversity occurs via expression of alternatively spliced forms of certain mGluR subtypes. Pin et al., PNAS 89: 10331 (1992), Minakami et al., BBRC 199:1136 (1994), JoIy et al., J. Neurosci. 15:3970 (1995).
- Metabotropic glutamate receptor subtypes may be subdivided into three groups, Group I, Group II, and Group III mGluRs, based on amino acid sequence homology, the second messenger systems utilized by the receptors, and by their pharmacological characteristics.
- Group I mGluR comprises mGluRl, mGluR5 and their alternatively spliced variants. The binding of agonists to these receptors results in the activation of phospholipase C and the subsequent mobilization of intracellular calcium-
- Group I mGluRs Attempts at elucidating the physiological roles of Group I mGluRs suggest that activation of these receptors elicits neuronal excitation.
- Various studies have demonstrated that Group I mGluRs agonists can produce postsynaptic excitation upon application to neurons in the hippocampus, cerebral cortex, cerebellum, and thalamus, as well as other CNS regions. Evidence indicates that this excitation is due to direct activation of postsynaptic mGluRs, but it also has been suggested that activation of presynaptic mGluRs occurs, resulting in increased neurotransmitter release. Baskys, Trends Pharmacol. Sci. 15:92 (1992), Schoepp, Neurochem. Int.
- mGluR activation has been suggested to play a modulatory role in a variety of other normal processes including synaptic transmission, neuronal development, apoptotic neuronal death, synaptic plasticity, spatial learning, olfactory memory, central control of cardiac activity, waking, motor control and control of the vestibulo-ocular reflex. Nakanishi, Neuron 13: 1031 (1994), Pin et al., Neuropharmacology 34:1, Knopfel et al, J. Med. Chem. 35:1417 (1995).
- Group I metabotropic glutamate receptors and mGluR5 in particular, have been suggested to play roles in a variety of pathophysiological processes and disorders affecting the CNS. These include stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, epilepsy, neurodegenerative disorders such as Alzheimer's disease and pain. Schoepp et al., Trends Pharmacol. Sci. 14: ⁇ 3 (1993), Cunningham et al., Life Sci. 54:135 (1994), Hollman et al., Ann. Rev. Neurosci. 77:31 (1994), Pin et al, Neuropharmacology 34:1 (1995), Knopfel et al, J. Med. Chem.
- Group I mGluRs appear to increase glutamate-mediated neuronal excitation via postsynaptic mechanisms and enhanced presynaptic glutamate release, their activation probably contributes to the pathology. Accordingly, selective antagonists of Group I mGluR receptors could be therapeutically beneficial, specifically as neuroprotective agents, analgesics or anticonvulsants. Further, it has also been shown that mGluR5 antagonists are useful for the treatment of addictions or cravings (for drugs, tobacco, alcohol, any appetizing macronutrients or nonessential food items).
- the group I receptor mGluR5
- the group I receptor has been implicated in a number of central nervous system disease states, including pain (Salt and Binns, 2000; Bhave, et al., 2001), anxiety (Spooren, et al., 2000; Tatarczynska, et al., 2001), addiction to cocaine (Chiamulera, et al., 2001) and schizophrenia (Chavez-Noriega, et al., 2002).
- the N-methyl-D-aspartate (NMDA) receptor an ionotropic glutamate receptor, has also been implicated in physiological and pathological processes.
- NMDA receptors produce a transient state of psychosis and schizophrenia-like cognitive deficits (Krystal, et al., Arch Gen Psychiatry, 51 : 199-214, 1994; Lahti, et al., Neuropsychopharmacol., 13: 9-19, 1995; Newcomer, et al., Neuropsychopharmacol., 20: 106-1 18, 1999).
- Pharmacological manipulation of NMDA receptor function may be critical for the treatment of many neurological and psychiatric disorders such as epilepsy, Alzheimer's disease, drug dependence and schizophrenia (Kemp and McKernan, 2002).
- NMDA receptors A functional interaction between NMDA receptors and mGluR5 has been demonstrated at a cellular level and at a behavioral level.
- activation of Group I mGluRs by DHPG enhanced NMDA-receptor mediated responses in mouse CAl pyramidal neurones (Mannaioni, et al., J. Neurosci., 21 :5925-5934, 2001).
- This effect was inhibited by MPEP, demonstrating that NMDA receptor function was enhanced through activation of mGluR5 (Mannaioni, et al., J. Neurosci., 21:5925-5934, 2001).
- mGluR5 Modulation of mGluR5 also altered the cognitive and behavioral abnormalities associated with NMDA receptor deficiency (Homayoun, et al., Neuropsychopharmacol., 29: 1259-1269, 2004). Together these data suggest that potentiation of mGluR5 could be beneficial in the treatment of disorders such as schizophrenia.
- the compounds of Formula I are useful as pharmacological tools in the development and standardization of in vitro and in vivo test systems for the evaluation of the effects of potentiators of mGluR related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
- the compounds of the present invention are potentiators of mGluR5 receptor function and are, therefore, useful in the treatment of neurological and psychiatric disorders associated with glutamate dysfunction.
- Ar 1 is selected from the group consisting of phenyl and pyridyl, which may be substituted with up to 4 substituents independently selected from the group consisting of alkyl, halo, haloalkyl and CN;
- Ar 2 is selected from the group consisting of phenyl and heteroaryl, which may be substituted with up to 4 substituents independently selected from the group consisting of alkyl, halo and haloalkyl;
- A is selected from the group consisting of C(O), C(S) and S(O) 2 ;
- X is selected from the group consisting of O and S;
- R 1 is selected from the group consisting of H and alkyl
- R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of H and alkyl; with the proviso that the compound is not l-[(benzyloxy)acetyl]-4-(4- chlorophenyl)piperazine.
- Another embodiment of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to Formula I and one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.
- Still other embodiments relate to a method of treatment of mGluR5-mediated disorders, comprising administering to a mammal a therapeutically effective amount of the compound according to Formula I.
- the present invention is based upon the discovery of compounds which are potentiators of metabotropic glutamate receptor function. More particularly, the compounds of the present invention exhibit activity as potentiators of mGluR5 receptor function and, therefore, are useful in therapy, in particular for the treatment of neurological and psychiatric disorders, Definitions
- alkyl as used herein means a straight- or branched-chain hydrocarbon radical having from one to six carbon atoms, and includes methyl, ethyl, propyl, isopropyl, t-butyl and the like.
- alkoxy as used herein means a straight- or branched-chain alkoxy radical having from one to six carbon atoms and includes methoxy, ethoxy, propyloxy, isopropyloxy, t- butoxy and the like.
- halo as used herein means halogen and includes fluoro, chloro, bromo, iodo and the like, in both radioactive and non-radioactive forms.
- haloalkyl as used herein means an alkyl group in which at least one H atom has been replaced by a halo atom, and includes groups such as CF 3 , CH 2 Br and the like.
- alkylene as used herein means a difunctional branched or unbranched saturated hydrocarbon radical having one to six carbon atoms, and includes methylene, ethylene, n- propylene, n-butylene and the like.
- aryl as used herein means an aromatic group having five to twelve atoms, and includes phenyl, naphthyl and the like.
- heteroaryl means an aromatic group having from 5 to 8 atoms which includes at least one heteroatom selected from the group consisting of N, S and O, and includes pyridyl, furyl, thienyl, thiazolyl, pyrazinyl, pyrimidinyl, oxazolyl and the like.
- pharmaceutically acceptable salt means either an acid addition salt or a basic addition salt which is compatible with the treatment of patients.
- a "pharmaceutically acceptable acid addition salt” is any non-toxic organic or inorganic acid addition salt of the base compounds represented by Formula I or any of its intermediates.
- Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
- Illustrative organic acids which form suitable salts include the mono-, di- and tricarboxylic acids.
- Illustrative of such acids are, for example, acetic, glycol ic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic, p-toluenesulfonic acid and other sulfonic acids such as methanesulfonic acid and 2-hydroxyethanesulfonic acid.
- Either the mono- or di-acid salts can be formed, and such salts can exist in either a hydrated, solvated or substantially anhydrous form.
- the acid addition salts of these compounds are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.
- the selection criteria for the appropriate salt will be known to one skilled in the art.
- Other non-pharmaceutically acceptable salts e.g. oxalates may be used for example in the isolation of compounds of Formula I for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- a "pharmaceutically acceptable basic addition salt” is any non-toxic organic or inorganic base addition salt of the acid compounds represented by Formula I or any of its intermediates.
- Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium or barium hydroxides.
- Illustrative organic bases which form suitable salts include aliphatic, alicyclic or aromatic organic amines such as methylamine, trimethyl amine and picoline or ammonia.
- the selection of the appropriate salt may be important so that an ester functionality, if any, elsewhere in the molecule is not hydrolyzed. The selection criteria for the appropriate salt will be known to one skilled in the art.
- Solvate means a compound of Formula I or the pharmaceutically acceptable salt of a compound of Formula I wherein molecules of a suitable solvent are incorporated in a crystal lattice.
- a suitable solvent is physiologically tolerable at the dosage administered as the solvate. Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the molecule is referred to as a hydrate.
- stereoisomers is a general term for all isomers of the individual molecules that differ only in the orientation of their atoms in space. It includes mirror image isomers (enantiomers), geometric (cis/trans) isomers and isomers of compounds with more than one chiral centre that are not mirror images of one another (diastereomers).
- treat or “treating” means to alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms of the named disorder or condition.
- terapéuticaally effective amount means an amount of the compound of Formula I which is effective in treating the named disorder or condition.
- pharmaceutically acceptable carrier means a non-toxic solvent, dispersant, excipient, adjuvant or other material which is mixed with the active ingredient in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to the patient.
- a pharmaceutical composition i.e., a dosage form capable of administration to the patient.
- a pharmaceutically acceptable oil typically used for parenteral administration.
- Ar 1 is selected from the group consisting of phenyl and pyridyl, which may be substituted with up to 4 substituents independently selected from the group consisting of alkyl, halo, haloalkyl and CN;
- Ar 2 is selected from the group consisting of phenyl and heteroaryl, which may be substituted with up to 4 substituents independently selected from the group consisting of alkyl, halo and haloalkyl;
- A is selected from the group consisting of C(O), C(S) and S(O) 2 ;
- X is selected from the group consisting of O and S;
- Y is selected from the group consisting of C and N;
- m is selected from the group consisting of 1 and 2;
- n is selected from the group consisting of 1 and 2;
- R 1 is selected from the group consisting of H and alkyl,
- R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of H and alkyl; with the proviso that the compound is not l-[(benzyloxy)acetyl]-4-(4- chlorophenyl)piperazine, l-[(benzyloxy)acetyl]-4-(2-methoxyphenyl)piperazine, 1 -[(benzyloxy)acetyl]-4-(4-methoxyphenyl)piperazine, 1 -[(benzyloxy)acetyl]-4-(3- chlorophenyl)piperazine, or 2-Benzyloxy- 1 -[4-(3-methyl-pyridin-2-yl)-piperazin- 1 -yl]- ethanone.
- Ar 1 is a phenyl group.
- Ar 2 is selected from the group consisting of phenyl, thienyl, thiazolyl and pyridyl.
- Ar 2 is selected from the group consisting of thienyl and pyridyl. It will be understood by those of skill in the art that when compounds of the present invention contain one or more chiral centers, the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I.
- optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate or chemical or enzymatic resolution methodology, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter.
- salts of the compounds of Formula I are also salts of the compounds of Formula I.
- pharmaceutically acceptable salts of compounds of the present invention are obtained using standard procedures well known in the art, for example, by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a salt with a physiologically acceptable anion.
- alkali metal such as sodium, potassium, or lithium
- alkaline earth metal such as a calcium
- quaternary ammonium salts can be prepared by the addition of alkylating agents, for example, to neutral amines.
- the compound of Formula I may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or p-toluenesulphonate.
- an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or p-toluenesulphonate.
- the compounds of the present invention may be formulated into conventional pharmaceutical compositions comprising a compound of Formula I 3 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier or excipient.
- the pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include, but are not limited to, powders, tablets, dispersible granules, capsules, cachets, and suppositories.
- a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents.
- a solid carrier can also be an encapsulating material.
- the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component.
- the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized moulds and allowed to cool and solidify.
- Suitable carriers include, but are not limited to, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low-melting wax, cocoa butter, and the like.
- composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it.
- a carrier which is thus in association with it.
- cachets are included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
- Liquid form compositions include solutions, suspensions, and emulsions.
- sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration.
- Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
- Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
- Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
- Exemplary compositions intended for oral use may contain one or more coloring, sweetening, flavoring and/or preservative agents.
- the pharmaceutical composition will include from about 0.05%w (percent by weight) to about 99%w, more particularly, from about 0.10%w to 50% w, of the compound of the invention, all percentages by weight being based on the total weight of the composition.
- a therapeutically effective amount for the practice of the present invention can be determined by one of ordinary skill in the art using known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented.
- the compounds according to the present invention selectively potentiate mGluR5 receptor function. Accordingly, the compounds of the present invention are expected to be useful in the treatment of conditions associated with inhibition of mGluR5 or conditions in which downstream pathways are altered by activation of mGluR5.
- the Group I mGluR receptors including mGluR5 are highly expressed in the central and peripheral nervous system and in other tissues. Thus, it is expected that the compounds of the invention are well suited for the treatment of mGluR5 -mediated disorders such as acute and chronic neurological and psychiatric disorders, gastrointestinal disorders, and chronic and acute pain disorders.
- the invention relates to compounds of Formula I, as defined herein, for use in therapy.
- the invention relates to compounds of Formula I, as defined herein, for use in treatment of mGluR5-mediated disorders.
- One embodiment of the invention relates to the use of a Formula I compound for the manufacture of a medicament for the treatment of schizophrenia.
- Another embodiment of the invention relates to the use of a Formula I compound for the manufacture of a medicament for the treatment of cognition.
- the invention also provides a method of treatment of mGluR5-mediated disorders and any disorder listed above, in a patient suffering from, or at risk of, said condition, which comprises administering to the patient an effective amount of a compound of Formula I, as hereinbefore defined.
- the dose required for the therapeutic or preventive treatment of a particular disorder will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
- the term “therapy” and “treatment” includes prevention or prophylaxis, unless there are specific indications to the contrary.
- the terms “therapeutic” and “therapeutically” should be construed accordingly.
- disorder means any condition and disease associated with metabotropic glutamate receptor activity.
- the compounds of Formula I are useful as pharmacological tools in the development and standardization of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of mGluR related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutics agents.
- Another aspect of the present invention provides processes for preparing compounds of Formula I 5 or salts or hydrates thereof. Processes for the preparation of the compounds in the present invention are described below.
- a transformation of a group or substituent into another group or substituent by chemical manipulation can be conducted on any intermediate or final product on the synthetic path toward the final product, in which the possible type of transformation is limited only by inherent incompatibility of other functionalities carried by the molecule at that stage to the conditions or reagents employed in the transformation.
- Such inherent incompatibilities, and ways to circumvent them by carrying out appropriate transformations and synthetic steps in a suitable order will be readily understood to the one skilled in the art of organic synthesis. Examples of transformations are given below, and it is to be understood that the described transformations are not limited only to the generic groups or substituents for which the transformations are exemplified.
- Microwave heating was performed in an Emrys Optimizer from Biotage / Personal Chemistry or a Smith Synthesizer Single-mode microwave cavity producing continuous irradiation at 2450 MHz (Personal Chemistry AB 5 Uppsala, Sweden).
- the pharmacological properties of the compounds of the invention can be analyzed using standard assays for functional activity.
- glutamate receptor assays are well known in the art as described in for example Aramori et al., Neuron 8:757 (1992), Tanabe et al., Neuron 8:169 (1992), Miller et al., J. Neuroscience 15: 6103 (1995), Balazs, et al, J. Neurochemistry 69:151 (1997).
- the methodology described in these publications is incorporated herein by reference.
- the compounds of the invention can be studied by means of an assay that measures the mobilization of intracellular calcium, [Ca 2+ Jj in cells expressing mGluR5.
- Intracellular calcium mobilization was measured by detecting changes in fluorescence of cells loaded with the fluorescent indicator fluo-3. Fluorescent signals were measured using the FLIPR system (Molecular Devices). A two addition experiment was used that could detect compounds that either activate or antagonize the receptor.
- FLIPR experiments were performed using a laser setting of 0.800 W and a 0.4 second CCD camera shutter speed. Each FLIPR experiment was initiated with 160 ⁇ L of buffer present in each well of the cell plate. After each addition of the compound, the fluorescence signal was sampled 50 times at 1 second intervals followed by 3 samples at 5 second intervals. Responses were measured as the peak height of the response within the sample period.
- EC5 0 and IC 5 0 determinations were made from data obtained from 8-point concentration response curves (CRC) performed in duplicate.
- Agonist CRC were generated by scaling all responses to the maximal response observed for the plate.
- Antagonist block of the agonist challenge was normalized to the average response of the agonist challenge in 14 control wells on the same plate.
- IP 3 Inositol Phosphate
- Antagonist and potentiator activity was determined by pre-incubating test compounds for 15 minutes, then incubating in the presence of glutamate or DHPG (EC80 for antagonists, EC30 for potentiators) for 30 minutes. Reactions were terminated by the addition of perchloric acid (5%). Samples were collected and neutralized, and inositol phosphates were separated using Gravity-Fed Ion-Exchange Columns.
- the compounds of the present invention were active in assays described herein at concentrations (or with ECso values) less than 10 ⁇ M.
- concentrations or with ECso values
- compounds 12, 23, 48 and 58 have EC50 values of 0.6, 5.1, 0.4 and 2.3 ⁇ M, respectively.
- the reaction mixture was filtered through diatomaceous earth and the filtrate was concentrated in vacuo.
- the residue was dissolved in ethyl acetate and washed with water (2 x 50 mL) and brine (50 mL).
- the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
- reaction flask was flushed with nitrogen for 5 minutes and then lithium bis(trimethylsilyl)amide (1 M in tetrahydrofuran, 6.99 mL, 6.99 mmol) was added in one portion.
- the reaction flask was sealed and the reaction mixture was stirred at room temperature for 72 hours.
- reaction mixture was heated to 80° C and then a mixture of tris(dibenzylidine acetone)dipalladium (31.1 mg, 0.015 mmol) and racemic 2,2'-bis(diphenylphosphino)-l,l'- binaphthyl (13.7 mg, 0.05 mmol) in toluene (2 mL) was slowly added to the reaction mixture.
- the reaction mixture was stirred at 110° C overnight and then concentrated in vacuo.
- the residue was dissolved in ethyl acetate (100 mL) and washed with water (3 x 50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
- the reaction mixture was diluted with water (1OmL) and extracted with ethyl acetate (3 x 5OmL). The combined organic layers were washed with brine (5OmL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
- glycolic acid (lOOmg, 1.31 mmol)
- l-(3-dimthylaminopropyl)- 3-ethylcarbodiimide hydrochloride (277.3mg, 1.45mmol)
- hydroxybenzotriazole (195.5mg, 1.45mmol)
- l-(2,4-dichlorophenyl)-piperazine dihydrochloride (439.8mg, 1.45mmol)
- triethylamine (0.55mL, 3.94mmol
- N,N-dimethylformamide 5mL
- the reaction was quenched with a saturated aqueous solution of ammonium chloride (1OmL) and extracted with ethyl acetate (3 x 1OmL). The organic extracts were combined, washed with brine (2OmL), dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in methanol (2OmL) followed by addition of sodium borohydride (0.14 g, 3.66 mmol). The resulting mixture was left stirring for 30 min. Methanol was removed in vacuo. Water (2OmL) was added to the residue and extracted with ethyl acetate (25mL). The organic phase was dried over sodium sulfate.
- the gum obtained was chromato graphed on silica gel using dichloromethane/methanol from 100% to 98% dichloromethane in a gradient fashion, to give the title compound as a white foamy solid (0.38 g, 30%). The material was used in next reaction without further purification.
- the solution was heated to 100 0 C for 2 h.
- the reaction was cooled to room temperature, diethyl ether (5mL) was added and the resulting mixture filtered through a bed of diatomaceous earth.
- the residue was chromatographed on silica gel using hexane/ethyl acetate from 100% to 95% hexane in a gradient fashion, to give the title compound as a gum (0.13 g, 43%).
- the residue was used as is without further purification.
- reaction mixture was stirred at 0° C for 15 minutes and then a solution of 2-chloro-l-[4-(2,4-dichloro-phenyl)-piperazin-l-yl]- ethanone (192 mg, 0.633 mmol) in tetrahydrofuran (1 mL) was added in one portion.
- the reaction mixture was stirred at room temperature overnight, quenched with water and extracted with dichloromethane. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602007002877T DE602007002877D1 (en) | 2006-01-17 | 2007-01-05 | PIPERAZINE AND PIPERIDINE AS mGluR5 AMPLIFIERS |
AU2007208500A AU2007208500A1 (en) | 2006-01-17 | 2007-01-05 | Piperazines and piperidines as mGluR5 potentiators |
JP2008558259A JP2009524702A (en) | 2006-01-17 | 2007-01-05 | Piperazines and piperidines as mGluR5 potentiators |
BRPI0706401-2A BRPI0706401A2 (en) | 2006-01-17 | 2007-01-05 | compound or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical composition, use of a compound, and method for treating or preventing neurological and psychiatric disorders associated with glutamate dysfunction in an animal |
EP07716336A EP1979320B1 (en) | 2006-01-17 | 2007-01-05 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS |
CA002636931A CA2636931A1 (en) | 2006-01-17 | 2007-01-05 | Piperazines and piperidines as mglur5 potentiators |
US12/160,959 US7935703B2 (en) | 2006-01-17 | 2007-01-05 | Piperazines and piperidines as Mglur5 potentiators |
AT07716336T ATE446287T1 (en) | 2006-01-17 | 2007-01-05 | PIPERAZINE AND PIPERIDINE AS MGLUR5 AMPLIFIER |
IL192474A IL192474A0 (en) | 2006-01-17 | 2008-06-26 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS |
NO20083390A NO20083390L (en) | 2006-01-17 | 2008-08-01 | Piperazines and piperidines as mGluR5 enhancers |
HK09102567.0A HK1122296A1 (en) | 2006-01-17 | 2009-03-18 | Piperazines and piperidines as mglur5 potentiators |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75899206P | 2006-01-17 | 2006-01-17 | |
US60/758,992 | 2006-01-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007087135A2 true WO2007087135A2 (en) | 2007-08-02 |
WO2007087135A3 WO2007087135A3 (en) | 2007-11-01 |
Family
ID=38181112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/000231 WO2007087135A2 (en) | 2006-01-17 | 2007-01-05 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS |
Country Status (21)
Country | Link |
---|---|
US (1) | US7935703B2 (en) |
EP (1) | EP1979320B1 (en) |
JP (1) | JP2009524702A (en) |
KR (1) | KR20080092374A (en) |
CN (1) | CN101405266A (en) |
AR (1) | AR058928A1 (en) |
AT (1) | ATE446287T1 (en) |
AU (1) | AU2007208500A1 (en) |
BR (1) | BRPI0706401A2 (en) |
CA (1) | CA2636931A1 (en) |
DE (1) | DE602007002877D1 (en) |
EC (1) | ECSP088677A (en) |
ES (1) | ES2333482T3 (en) |
HK (1) | HK1122296A1 (en) |
IL (1) | IL192474A0 (en) |
NO (1) | NO20083390L (en) |
RU (1) | RU2008129129A (en) |
TW (1) | TW200734313A (en) |
UY (1) | UY30087A1 (en) |
WO (1) | WO2007087135A2 (en) |
ZA (1) | ZA200805726B (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008152090A1 (en) * | 2007-06-14 | 2008-12-18 | Glaxo Group Limited | Novel compound |
WO2009099177A1 (en) * | 2008-02-06 | 2009-08-13 | Taisho Pharmaceutical Co., Ltd. | Amino imidazole derivative |
WO2013060860A1 (en) * | 2011-10-27 | 2013-05-02 | National University Of Ireland, Maynooth | N-acyl-n'-phenylpiperazine derivatives as srbp modulators for use in the treatment of diabetes and obesity |
WO2013087805A1 (en) * | 2011-12-14 | 2013-06-20 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors |
WO2013087739A1 (en) * | 2011-12-13 | 2013-06-20 | Boehringer Ingelheim International Gmbh | 4-aryl imidazole derivatives as mglur5 positive allosteric modulators |
WO2013087806A1 (en) * | 2011-12-14 | 2013-06-20 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors |
WO2013087807A1 (en) * | 2011-12-14 | 2013-06-20 | Boehringer Ingelheim International Gmbh | 4-aryl imidazole derivatives as mglu5 positive allesteric modiulators |
US8642774B2 (en) | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2134687A1 (en) * | 2007-03-09 | 2009-12-23 | AstraZeneca AB | Piperazine and piperidine mglur5 potentiators |
JP6416125B2 (en) * | 2013-02-04 | 2018-10-31 | プレクストン・セラピューティクス・ソシエテ・アノニム | mGluR3 positive allosteric modulator |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0105397A1 (en) * | 1982-09-30 | 1984-04-18 | MERCK PATENT GmbH | Sulphuric indole derivatives |
WO2003093236A1 (en) * | 2002-05-02 | 2003-11-13 | Euro-Celtique, S.A. | 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor |
WO2004089470A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | New amide derivatives and pharmaceutical use thereof |
WO2005030128A2 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
WO2006002349A1 (en) * | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001261657A (en) * | 2000-03-17 | 2001-09-26 | Yamanouchi Pharmaceut Co Ltd | Cyanophenyl derivative |
JP2005502623A (en) * | 2001-07-02 | 2005-01-27 | ノボ ノルディスク アクティーゼルスカブ | Substituted piperazines and diazepanes |
WO2004089415A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
-
2006
- 2006-12-29 TW TW095149847A patent/TW200734313A/en unknown
-
2007
- 2007-01-05 BR BRPI0706401-2A patent/BRPI0706401A2/en not_active IP Right Cessation
- 2007-01-05 WO PCT/US2007/000231 patent/WO2007087135A2/en active Application Filing
- 2007-01-05 AR ARP070100050A patent/AR058928A1/en unknown
- 2007-01-05 ES ES07716336T patent/ES2333482T3/en active Active
- 2007-01-05 CN CNA2007800094331A patent/CN101405266A/en active Pending
- 2007-01-05 JP JP2008558259A patent/JP2009524702A/en active Pending
- 2007-01-05 RU RU2008129129/04A patent/RU2008129129A/en not_active Application Discontinuation
- 2007-01-05 AU AU2007208500A patent/AU2007208500A1/en not_active Abandoned
- 2007-01-05 CA CA002636931A patent/CA2636931A1/en not_active Abandoned
- 2007-01-05 UY UY30087A patent/UY30087A1/en not_active Application Discontinuation
- 2007-01-05 US US12/160,959 patent/US7935703B2/en not_active Expired - Fee Related
- 2007-01-05 KR KR1020087017280A patent/KR20080092374A/en not_active Application Discontinuation
- 2007-01-05 EP EP07716336A patent/EP1979320B1/en active Active
- 2007-01-05 DE DE602007002877T patent/DE602007002877D1/en active Active
- 2007-01-05 AT AT07716336T patent/ATE446287T1/en not_active IP Right Cessation
-
2008
- 2008-06-26 IL IL192474A patent/IL192474A0/en unknown
- 2008-06-30 ZA ZA200805726A patent/ZA200805726B/en unknown
- 2008-08-01 NO NO20083390A patent/NO20083390L/en not_active Application Discontinuation
- 2008-08-12 EC EC2008008677A patent/ECSP088677A/en unknown
-
2009
- 2009-03-18 HK HK09102567.0A patent/HK1122296A1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0105397A1 (en) * | 1982-09-30 | 1984-04-18 | MERCK PATENT GmbH | Sulphuric indole derivatives |
WO2003093236A1 (en) * | 2002-05-02 | 2003-11-13 | Euro-Celtique, S.A. | 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor |
WO2004089470A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | New amide derivatives and pharmaceutical use thereof |
WO2005030128A2 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
WO2006002349A1 (en) * | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008152090A1 (en) * | 2007-06-14 | 2008-12-18 | Glaxo Group Limited | Novel compound |
WO2009099177A1 (en) * | 2008-02-06 | 2009-08-13 | Taisho Pharmaceutical Co., Ltd. | Amino imidazole derivative |
US10077243B2 (en) | 2009-12-18 | 2018-09-18 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
WO2013060860A1 (en) * | 2011-10-27 | 2013-05-02 | National University Of Ireland, Maynooth | N-acyl-n'-phenylpiperazine derivatives as srbp modulators for use in the treatment of diabetes and obesity |
US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8642774B2 (en) | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
WO2013087739A1 (en) * | 2011-12-13 | 2013-06-20 | Boehringer Ingelheim International Gmbh | 4-aryl imidazole derivatives as mglur5 positive allosteric modulators |
US8796467B2 (en) | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
US8716277B2 (en) | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
WO2013087807A1 (en) * | 2011-12-14 | 2013-06-20 | Boehringer Ingelheim International Gmbh | 4-aryl imidazole derivatives as mglu5 positive allesteric modiulators |
WO2013087806A1 (en) * | 2011-12-14 | 2013-06-20 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors |
US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
WO2013087805A1 (en) * | 2011-12-14 | 2013-06-20 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors |
US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
Also Published As
Publication number | Publication date |
---|---|
US7935703B2 (en) | 2011-05-03 |
ES2333482T3 (en) | 2010-02-22 |
ZA200805726B (en) | 2009-05-27 |
EP1979320A2 (en) | 2008-10-15 |
EP1979320B1 (en) | 2009-10-21 |
ATE446287T1 (en) | 2009-11-15 |
JP2009524702A (en) | 2009-07-02 |
DE602007002877D1 (en) | 2009-12-03 |
IL192474A0 (en) | 2009-02-11 |
UY30087A1 (en) | 2007-08-31 |
TW200734313A (en) | 2007-09-16 |
AR058928A1 (en) | 2008-03-05 |
BRPI0706401A2 (en) | 2011-03-29 |
KR20080092374A (en) | 2008-10-15 |
HK1122296A1 (en) | 2009-05-15 |
RU2008129129A (en) | 2010-02-27 |
CA2636931A1 (en) | 2007-08-02 |
WO2007087135A3 (en) | 2007-11-01 |
NO20083390L (en) | 2008-10-14 |
US20090023711A1 (en) | 2009-01-22 |
ECSP088677A (en) | 2008-09-29 |
CN101405266A (en) | 2009-04-08 |
AU2007208500A1 (en) | 2007-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1979320B1 (en) | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | |
US20100144710A1 (en) | Piperazine and Piperidine MGLUR5 Potentiators | |
EP1337518B1 (en) | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor | |
JP4980928B2 (en) | G protein-coupled receptor (GPR116) agonist and use thereof for the treatment of obesity and diabetes | |
JP4958560B2 (en) | Heterocyclic derivatives as GPCR receptor agonists | |
JP4669836B2 (en) | Piperidinyl- and piperazinyl-alkyl carbamate derivatives, their preparation and therapeutic use | |
KR100228608B1 (en) | Piperazine derivatives | |
KR20150116907A (en) | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842 | |
AU2005214376A1 (en) | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists | |
KR100191362B1 (en) | Piperazine derivatives | |
WO2013112323A1 (en) | Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors | |
DE60001586T2 (en) | DIPHENYL-PIPERIDINE DERIVATIVES | |
CA2787248A1 (en) | Piperazine compound having a pgds inhibitory effect | |
JP2009536212A (en) | Polycyclic heterocyclic compounds and their use as modulators of metabotropic glutamate 5 receptors | |
KR20080050569A (en) | Acetylenic piperazines as metabotropic glutamate receptor antagonists | |
US20070049578A1 (en) | Cinnamamide compounds as metabotropic glutamate receptor antagonists | |
WO2005030754A1 (en) | Indole or quinoline derivatives as non-pepticid npy y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity | |
JP2013505297A (en) | O-Benzylnicotinamide analogs as positive allosteric modulators of mGluR5 | |
TW200404067A (en) | New compounds | |
JP3012048B2 (en) | Piperazine derivative | |
MX2008008888A (en) | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | |
JP7168456B2 (en) | Indoline derivatives and methods of using and producing them | |
AU2002215294B2 (en) | Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor | |
AU2002215294A1 (en) | Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor | |
MXPA06009022A (en) | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007208500 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5752/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2636931 Country of ref document: CA Ref document number: MX/a/2008/008888 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007716336 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008071169 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008558259 Country of ref document: JP Ref document number: 12008501665 Country of ref document: PH Ref document number: 1020087017280 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007208500 Country of ref document: AU Date of ref document: 20070105 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 570536 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2008129129 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12160959 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780009433.1 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: PI0706401 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080715 |